Background
Over-the-counter (OTC) availability of HIV PrEP could improve use and persistence by removing the requirement of frequent clinician visits, laboratory testing, and associated costs. However, it is unknown whether the benefits of increased access would outweigh the potential risks associated with reduced monitoring.
Methods
Using an agent-based model of men who have sex with men in Atlanta, Georgia, we modeled the potential impact of OTC availability on PrEP coverage and 3 safety outcomes: glomerular filtration rate (GFR) decreases below 60 mL/min, drug resistance, and post-discontinuation hepatitis B virus (HBV) flares. Our primary intervention scenario assumed a 30% increase in PrEP users with OTC PrEP, as well as relaxed behavioral indications, reduced baseline HIV screening, longer persistence, and longer intervals between follow-up tests. Primary analyses investigated the risk-benefit tradeoffs over 10 years of this scenario compared to a reference scenario without OTC PrEP and with perfect adherence to monitoring recommendations for prescription PrEP. We also assessed OTC PrEP implementation scenarios that could improve risk-benefit tradeoffs.
Results
Compared to an idealized prescription-PrEP-only scenario, our primary OTC PrEP scenario would avert an additional 9.1% of HIV infections over 10 years. For every 100 infections averted, there would be an additional 326 GFR decreases below 60 mL/min, 35 cases of drug resistance (32 to FTC and 3 to TDF), and 3 HBV flares. Implementing OTC PrEP with increased renal function testing for older persons and those with renal disease would reduce by 30% the number of PrEP users remaining on PrEP after a GFR drop below 60 mL/min. With all OTC PrEP users accessing HIV screening prior to initiation, there would be only 8 additional cases of drug resistance per 100 infections averted (7 to FTC and 1 to TDF). Scenarios where prescription PrEP users switched to OTC PrEP resulted in poorer risk-benefit tradeoffs than scenarios where OTC PrEP engaged new users.
Conclusions
OTC availability of PrEP could expand access and thus prevent new HIV infections, especially if it engaged new users. Reduced monitoring with OTC PrEP would have minimal impact on HBV flares but could increase drug resistance and undetected renal dysfunction, though few cases would lead to treatment failure or serious renal events. Drug label instructions (e.g., “see a doctor first if…”) and measures to facilitate self-monitoring could improve the risk-benefit tradeoffs of OTC PrEP.